Skip to main content
Saudi Journal of Biological Sciences logoLink to Saudi Journal of Biological Sciences
. 2020 Sep 25;27(12):3290–3300. doi: 10.1016/j.sjbs.2020.09.042

Caspase dependent apoptotic activity of polycyclic cage-like heterocyclic hybrids

Raju Suresh Kumar a,, Abdulrahman I Almansour a, Natarajan Arumugam a, D Kotresha b, Janardhana Papayya Balakrishna c
PMCID: PMC7715051  PMID: 33304134

Abstract

A small library of cage-like heterocyclic hybrids encompassing pyrroloisoquinolines, pyridinone and acenaphthene structural moieties have been synthesized and tested for their potential as anticancer agents against HCT116 and JURKAT cell lines. The results revealed that these cell lines are more sensitive towards compound 1g and it showed dose dependent cytotoxic effect at 48 hrs of incubation. The IC50 values of compound 1g against HCT116 and JURKAT cell lines are 12.14 ± 1.53 and 10.68 ± 0.68 µM, respectively. Further studies on the determination of mechanism of action of compound 1g discovered that it brought the cell death by inducing Caspase 3 dependent apoptosis and also by arresting the cell cycle at S phase. These studies revealed that compound 1g can be recommended as a potential anti-cancer agent.

Keywords: Cage-like heterocyclic hybrids, HCT116, JURKAT, Apoptosis, Cell cycle, TUNEL Assay, Caspase 3

1. Introduction

Uncontrolled division and differentiation of cells is known as cancer. Worldwide cancer is a major cause of mortality (Ames et al., 1995). After cardiovascular diseases cancer was found second leading cause with the higher mortality rate in the United States, while great steps have been made in the treatment of cancer over the past 50 years, it remains to be a foremost health concern and, hence, broad efforts have been devoted in search of new therapeutic approaches (Stewart and Kleihues, 2014, Kanavos, 2006). Due to advances in the early detection, diagnosis and preventive treatments reduction in death rates were observed (Gralow et al., 2008). Over 100 years of the research demonstrated that the cancer could be treated effectively through various different strategies such as surgery, chemotherapy and radiotherapy. The treatment strategies when combined or applied alone can significantly affect the growth of the tumor (Wolinsky et al., 2012, Chen et al., 2016). The combination therapy can be impactful on various solid cancers such as, colon, breast etc. Once the metastasis starts in the tumor, the treatment for the specific cancer becomes more complicated (Weidner 1995). There are still most of the significant challenges remaining for various different cancer one of the widely known example is glioblastoma, in which the early detection, diagnosis, chemotherapy and even surgery results into failure to extend the lifespan and survival beyond 2 years (Grossman and Batara, 2004, Maier-Hauff et al., 2007). Colon cancer is one of the common cancers in the US and is proved to be a second largest cause of deaths. Differences in the right and left colon may be due to histological, genetic and immunological features (Lim et al., 2017, Todaro et al., 2007). Typically, colon cancer can occur at any age, it starts with the benign cancer called polyps occurs inside the colon. As time goes, the cancer becomes cancer of the colon (Todaro et al., 2007). In the development phase of the colon cancer, so many treatment strategies are available for the prevention and control. There are no prominent symptoms are noticed in the early stages of the cancer. In the progression stage, the symptoms are more noticeable (Adrouny, 2002, Boyle et al., 2000).

Heterocyclic hybrids possessing Nitrogen are prevalent in myriad natural products and used as honored structures in small molecules (Gomtsyan, 2012, Eicher et al., 2012). Among diverse biologically potent alkaloids, pyrroloisoquinoline structural units are common and present in lycorine class of Amaryllidaceae alkaloids (Eicher et al., 2012, Nair et al., 2016) and phenanthroindolizidine alkaloids (Pereira et al., 2015) besides, these structural subunits are also prevalent in Crispine A (Zhang et al., 2002), Harmicine (Kam and Sim, 1998, Chakraborty and Jana, 2013), Erysotramidine and Lamellarins (Andreev et al., 2016) displaying valuable therapeutic properties. Furthermore, some synthetic derivatives possessing this heterocyclic subunit also showed potential pharmacological properties (Sorgi et al., 1990). Research studies on anticancer drugs discloses that pyridinone derivatives with an α,β-unsaturated carbonyl group shown fluorescent properties emphasizing their potential as theranostic agents and displayed effective activity against cancer cell lines. In particular, 3,5-bis(arylidene)-4-piperidones reveal low-micromolar to sub-micromolar IC50 values towards a number of cancer cell lines (Sorgi et al., 1990, Santiago-Vazquez et al., 2014). Acenaphthopyrrole derivatives also displayed sub-micromolar activity against specific cancer cell lines (Liu et al., 2006, Zhang et al., 2006). Consequently, the heterocyclic hybrids comprising pyrrolo[1,2-b]isoquinolines, pyridinone and acenaphthene structural sub units could be valuable in forthcoming studies for drug development. Contemplations on the anticancer drugs led us to focus our research on novel anticancer agents with high selectivity and diminished toxicity. In our recent study (Kumar et al., 2020), we explored the synthesis and anticancer evaluation of a cage-like heterocyclic hybrid derived from a dipolarophile with phenyl groups. In the present study, we reported the apoptotic inducing ability of cage-like heterocyclic hybrids possessing different substituted aryl rings, biologically active pyrroloisoquinoline, pyridinone and acenaphthene structural moieties.

2. Materials and methods

2.1. Chemistry

Melting points of the cage compounds were determined by open capillary tubes and are uncorrected. 1H and 13C Nuclear Magnetic Spectra (NMR) were documented on a Bruker 500 MHz instrument in CDCl3 using Tetramethylsilane (TMS) as internal standard and standard Bruker software was used. IR spectra of the cage compounds were recorded on a Perkin Elmer system 2000 FT-IR (KBr). Elemental analyses were performed on a Perkin Elmer 2400 Series II Elemental CHNS analyzer.

2.1.1. Cage-like heterocyclic hybrid 1g

Pale brown solid, (90%); mp = 189–191 °C; IR (KBr): 1597, 1685, 3426 cm−1; 1H NMR (500 MHz, CDCl3): δH 2.83 (1H, dd, J = 14.0, 8.5 Hz, H-18), 2.98 (1H, d, J = 12.0 Hz, H-25), 3.05 (1H, dd, J = 14.5, 5.0 Hz, H-18), 3.21 (1H, d, J = 14.0 Hz, H-13), 3.32 (1H, d, J = 16.5 Hz, H-24), 3.57–3.64 (2H, m, H-13 and H-24), 4.22–4.24 (2H, m, H-20 and H-25), 4.39–4.42 (1H, m, H-19), 6.17 (1H, s, H-26), 6.32 (2H, d, J = 8.5 Hz, ArH), 6.71 (1H, d, J = 7.0 Hz, ArH), 7.02 (1H, d, J = 7.0 Hz, ArH), 7.05 (2H, d, J = 8.5 Hz, ArH), 7.10–7.12 (1H, m, ArH), 7.16 (1H, d, J = 7.5 Hz, ArH), 7.21 (1H, d, J = 7.0 Hz, ArH) 7.28–7.38 (3H, m, ArH), 7.45–7.48 (2H, m, ArH), 7.55 (1H, d, J = 8.5 Hz, ArH), 7.60 (1H, d, J = 7.0 Hz, ArH), 7.71 (2H, d, J = 8.5 Hz, ArH). 13C NMR (125 MHz, CDCl3): δC 34.31, 47.93, 51.72, 52.85, 56.33, 63.02, 72.66, 94.43, 121.20, 124.31,125.85, 125.95, 126.37, 126.53, 127.40, 127.50, 127.65, 128.08, 128.78, 128.85, 130.27, 130.74, 131.66, 132.22, 133.29, 133.56, 134.30, 134.43, 134.77, 135.15, 135.18, 135.35, 136.61, 136.76, 138.38, 196.51. Anal. calcd for C40H30Cl2N2O2: C, 74.88; H, 4.71; N, 4.37%; found: C, 74.69; H, 4.83; N, 4.51%.

2.2. Biology

Cell lines (HCT116, JURKAT) were obtained from ATCC (American Type Culture Collection) situated in Virginia, USA. D-MEM (cat no. AL111), Fetal Bovine Serum (cat no. RM10432), D-PBS (cat no. TL1006) was purchased from Himedia, Camptothecin (Cat No: C9911) was procured from Sigma Alddrich, India, Propidium Iodide (cat 556463); APO-DIRECT™ Kit (cat no. 556381); FITC Rabbit Anti- Active Caspase-3 (cat no. 560901); FITC Annexin V Apoptosis Detection Kit I (cat no. 556547); MitoScreen Kit-JC-1 (cat No. 551302) were collectively purchased from BD biosciences.

2.2.1. Cell line and cell culture

The HCT116 and JURKAT cell lines were obtained from ATCC (American Type Culture Collection) situated in Virginia, USA. The cell line were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) and for enhancement for growth addition with 10% of fetal bovine serum, 100 µg·mL−1 of streptomycin, 100 UI·mL−1 of penicillin and the cultures were being maintained at 37 °C within a humidified air atmosphere with 5% (V/V) CO2.

2.2.2. Maintenance of cell line

The vial containing the HCT-116 and JURKAT cell lines acquired from ATCC was taken from liquid nitrogen freezer and immediately placed in a 37 °C water bath. It was whirled until a small ice crystal remained. The entire content was transferred into a 15 mL centrifuge tube. Later the cryopreservation medium was removed by centrifuging for 10 min at 2000 RPM, at room temperature. Then the cell pellet was washed with fresh cell culture medium to remove residual DMSO. The cells were maintained in a T25 flask at recommended density and once 80% confluency was reached, the cells were sub-cultivated in 1:4 ratio.

2.2.3. Apoptosis assay

Annexin V/FITC Kit (BD Biosciences, Catalogue no. 556547), was used for performance of apoptosis assay and the fluorescence intensities of annexin-V-FITC and PI in drug treated and control cells were estimated by using flow cytometer. One million of HCT-116 cells were seeded in required number of wells of a 6-well plate and cultured for 12 hrs. Later, the spent medium was removed and cells were cultured in medium containing test compounds at IC50 value for 48 hrs. After incubation, the cells were collected by trypsinization and washed twice with PBS. The cells were resuspended in 100 μL of annexin V-FITC binding buffer (1×) and 5 μL annexin V-FITC and incubated in the dark for 10 min at 25 °C. The cells were then washed with PBS by centrifugation at 2000 rpm for 5 min. The cell pellet was resuspended in 500 μL annexin V-FITC binding buffer (1×) and 5 μL PI, followed by flow cytometric analysis.

2.2.4. Assessment of mitochondrial membrane potential (ΔΨ m)

1 × 106 HCT-116 cells/well were seeded in a 6-well plate and cultured for overnight. After adherence to the plastic surface, the cells were incubated in medium containing compound 1g and CPT at their IC50 values for 48 hrs. The spent medium was discarded and the cells were harvested by trypsinization and PBS wash. 70% ice-cold ethanol was used to fix the cells by incubating at −20 °C for 30 min. Then, 0.5 mL of freshly prepared JC-1 solution was added to each cell pellet and incubated for 10–15 min at 37 °C in a CO2 incubator. 1 mL of assay buffer was used to wash the cells and then resuspended the cell pellets in 0.5 mL of assay buffer. Mitochondrial membrane potential (ΔΨ m) was determined by BD FACS Calibur.

2.2.5. Caspase 3 expression studies:

6-well plate was used for seeding of HCT-116 cells (1 × 106 cells/well). After overnight culture at 37 °C in a CO2 incubator, the spent medium was replaced with culture medium containing compound 1g and CPT at IC50 values and incubated for 48 hrs. Cells were collected by trypsinization and harvested by thorough PBS wash. 70% ice cold ethanol was applied to fix and permeabilize the cells by incubating at −20 °C temperature for 30 min. After, PBS wash the cells were incubated with 20 µL of Caspase 3 -FITC for 1 hr. at RT in dark. The cells were washed with PBS to remove unbound antibodies and resuspended in 0.5 mL of PBS. The Caspase3 expression was determined by BD FACS Calibur.

2.2.6. Cell cycle analysis

Initially HCT-116 cells (1 × 106 cells/well) were seeded in a 6-well plate and cultured for overnight and then exposed to IC50 values of test sample 1g, positive control CPT respectively and the untreated cells were used as negative control. Post incubation of 48 hrs, the untreated cells and treated cells were washed twice with 1xPBS. The cells were then fixed and permeabilized with 70% ice cold ethanol at −20 °C for 30 min. These fixed cells were washed with PBS and resuspended with 50 μL of RNase A solution and 400 μL of Propidium Iodide solution (per million cells), vortexed and incubated for 10 min at RT. The cell cycle distribution in 10,000 cells was determined by flow cytometry.

2.2.7. Statistical analysis

The data are represented as the mean ± standard deviation (SD). SPSS software version 21.0 was used for the data analysis.

3. Results and discussion

3.1. Synthesis

In the present study, a series of heterocyclic hybrids 1(a-l) comprising biologically active pyrroloisoquinoline, pyridinone and acenaphthene structural units in a cage-like framework have been achieved (see Scheme 1) following the experimental procedure reported by us (Kumar et al., 2020). All the compounds were obtained in good to excellent yields and their structure was unambiguously derived using spectroscopic techniques. The synthesized cage-like heterocyclic hybrids 1(a-l) were evaluated for their potential as anticancer agents.

Scheme 1.

Scheme 1

Cage-like heterocyclic hybrids 1(a-l).

3.2. Antiproliferative activity using MTT assay

MTT assay is used as a sensitive, quantitative, and reliable colorimetric assay to measure viability, proliferation, and activation of cells. The MTT assay was performed to assess the IC50 for synthesized compounds. Initially, synthesized compounds were evaluated at 25, 50, 75, 100, 125 µM concentrations. At this concentration, all compounds exhibit significant and very potent activity against HCT-116 (colon cancer) and JURKAT (human T lymphocyte cells) cell lines. Based on significant activity, we further evaluated compounds at lower concentrations at 1, 5, 10, 15, and 20 µM concentration. Here, a dose-dependent reduction in the cell viability was detected upon treatment with various compounds. Here, camptothecin was used as standard drugs. From the entire datasets of twelve analogs, compound 1j exhibits potent activity against HCT-116 cell line with an IC50 value of 10.37 µM, which was greater than standard compound camptothecin (14 µM) upon 48 hrs of the incubation time. Moreover, Compound 1g exhibits potent activity on both HCT-116 and JURKAT cell lines with IC50 values 12.14 and 10.68 µM, correspondingly (Fig. 1). The structure of all synthesized analogs along with IC50 against HCT-116 and JURKAT cell lines are depicted in Table 1.

Fig. 1.

Fig. 1

Bar graphs representing % of cell viability after exposing to increasing concentrations of compound 1g for 48 hrs. (a) % of JURKAT cell viability; (b) % of HCT116 cell viability.

Table 1.

IC50 value of synthesized analogous against HCT116 and JURKAT cell lines based on MTT antiproliferative activity assay.

Entry Compound 24 hrs. treatment
IC50 values
48 hrs. treatment
IC50 values
HCT116 JURKAT HCT116 JURKAT
1 graphic file with name fx1.gif 27.33 ± 1.13 64.66 ± 0.58 NA 34.55 ± 0.74



2 graphic file with name fx2.gif 13.23 ± 0.56 72.35 ± 0.78 12.27 ± 1.11 30.11 ± 1.34



3 graphic file with name fx3.gif 30.97 ± 1.31 NA 11.49 ± 0.89 67.29 ± 0.93



4 graphic file with name fx4.gif 59.42 ± 1.37 NA 10.98 ± 0.73 63.6 ± 0.13



5 graphic file with name fx5.gif NA 120.52 ± 0.85 NA 64.35 ± 0.54



6 graphic file with name fx6.gif 13.27 ± 0.64 14.64 ± 1.14 NA 10.68 ± 0.74



7 graphic file with name fx7.gif 13.36 ± 0.83 15.75 ± 0.81 12.14 ± 1.53 10.68 ± 0.68



8 graphic file with name fx8.gif NA NA NA 71.69 ± 0.73



9 graphic file with name fx9.gif 92.705 ± 0.66 15.03 ± 1.21 NA 10.70 ± 1.37



10 graphic file with name fx10.gif 9.79 ± 0.73 15.61 ± 0.37 10.37 ± 0.88 10.17 ± 1.42



11 graphic file with name fx11.gif 14.02 ± 1.11 NA 10.82 ± 0.83 68.21 ± 0.52



12 graphic file with name fx12.gif 14.24 ± 0.74 NA 11.65 ± 1.04 69.48 ± 1.09



13 CPT 23.44 ± 0.81 18.33 ± 0.67 14.57 ± 0.43 13.69 ± 0.69

3.3. Apoptosis assay

To identify whether compound 1g exhibits apoptosis, we performed apoptosis assay using Annexin V/FITC, and the fluorescence intensities of FITC-conjugated annexin-V and PI in cells and were analyzed using flow cytometry (Fig. 2). Apoptosis is the critical process for the death of the cancer cells. Upon exposure with compound 1g at IC50 value, 44.34% cells display early apoptosis and 14.52% cells display late apoptosis. The results indicated that compound 1g significantly induces apoptosis in the HCT-116 cell lines (Fig. 3).

Fig. 2.

Fig. 2

Graph of FITC-Annexin V Vs PI staining against HCT-116 cell lines upon exposure with analogue 1g and camptothecin at IC50 value; (A) Control untreated HCT-116 cells; (B) HCT-116 Cells treated with standard drug camptothecin at IC50 value; (C) HCT-116 cells treated with 1g at IC50 value.

Fig. 3.

Fig. 3

Graph % of cells in each quadrant Vs compounds upon treatment with standard drug and analogue 1g.

3.4. Cell cycle analysis

As shown in Fig. 4, cell cycle analysis of HCT-116 cells revealed that the cells treated with concentrations IC50 of 1g has high cells at the G0/G1 phase. The positive control, camptothecin (14 uM) shown the highest number of cells at the sub G0/G1 phase. There is no significant alteration observed amongst all the groups for the G2/M phase and S phase. Here, most active analogue 1g and camptothecin follows similar pattern in cell cycle upon treatment at IC50 concentration (Fig. 5).

Fig. 4.

Fig. 4

FACS Histograms showing the phases of cell cycle distribution in the HCT-116 cell line treated with analogue 1g and standard drug camptothecin at IC50 value.

Fig. 5.

Fig. 5

Bar Plots of cell cycle phases of cells treated with CPT and its analogue 1g at IC50 value.

3.5. Caspase 3 induction assay

Caspase 3 was up-regulated, as shown in Fig. 6. Analogue 1g shown the highest induction of caspase 3 while there was the lowest expression in solvent treated cells (negative control). The results suggest that as analogue 1g exhibits significant caspase 3 induction which is also higher than standard drug camptothecin upon treatment with IC50 concentration (Fig. 7).

Fig. 6.

Fig. 6

Overlay of fluorescence intensities of caspase 3-FITC expression in HCT116 treated with IC50 values of 1g and CPT for 48 hr.

Fig. 7.

Fig. 7

Graph depicting the Caspase 3 quantification in HCT-116 cells treated with analogue 1g and positive control camptothecin.

3.6. Assessment of mitochondrial membrane potential (ΔΨ m)

Mitochondria are related to apoptosis initiation and progression. Disturbance in MMP can release proapoptotic factors, such as cytochrome c and apoptosis-inducing factor. During apoptosis, the collapse of the MMP coincides with the opening of the mitochondrial permeability transition pores, leading to the release of cytochrome c into the cytosol, which in turn triggers other downstream events in the apoptotic cascade. Upon exposure with analogue 1g and camptothecin increase in mitochondrial membrane potential was observed (Fig. 8, Fig. 9).

Fig. 8.

Fig. 8

Graph of FLT-JC1 Vs FLT-JC2 against HCT-116 cell lines upon exposure with analogue 1g and camptothecin at IC50 value; (A) Control untreated HCT-116 cells; (B) HCT-116 Cells treated with standard drug camptothecin at IC50 value; (C) HCT-116 Cells treated with 4 g at IC50 value.

Fig. 9.

Fig. 9

Graph depicting the JC1 quantification in HCT-116 cells treated with analogue 1g and positive control camptothecin.

3.7. TUNEL assay

TUNEL is a method for evaluation of apoptotic DNA fragmentation, widely used to identify and quantify apoptotic cells, or to detect excessive DNA breakage in individual cells. Here, upon treatment with analogue 1g and camptothecin; 1g treated cells show greater number of apoptotic cells as compare to control cells (Fig. 10, Fig. 11).

Fig. 10.

Fig. 10

Overlay of fluorescence intensities of FITC-dUTP expression in HCT116 treated with IC50 values of 1g and CPT for 48 hr.

Fig. 11.

Fig. 11

Graph of FITC-dUTP Vs Count against HCT-116 cell lines upon treatment with analogue 1g and camptothecin at IC50 value.

4. Conclusions

A small library of cage-like heterocyclic hybrids 1(a-l) encompassing biologically active pyrroloisoquinolines, pyridinone and acenaphthene structural moieties have been synthesized and tested for their potential as anticancer agents against HCT116 and JURKAT cell lines. The analogues exhibit dose dependent reduction with significant anticancer activity. The results of MTT assay reveals that analogue 1g able to inhibit HCT-116 (colon cancer cell line) and JURKAT cell line with IC50 values 12.14 and 10.68 µM individually. Based on excellent inhibitory activity in MTT assay, analogue 1g was further evaluated for apoptosis and cell cycle analysis. The results suggest that analogue 1g able to induce apoptosis at early stage in HCT-116 cell line and also arrest cell line which is equivalent to standard drug camptothecin. Further, analogue 1g also increase threshold of MMP which is important for apoptosis of cancer cells. The results of in vitro anticancer activity strongly indicate that 1g may become a potential molecule to develop as drug candidate.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The project was supported by Researchers Supporting Project number (RSP-2020/231), King Saud University, Riyadh, Saudi Arabia.

Footnotes

Peer review under responsibility of King Saud University.

References

  1. Adrouny A.R. Univ. Press of Mississippi; 2002. Understanding Colon Cancer. [Google Scholar]
  2. Ames B.N., Gold L.S., Willett W.C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. 1995;92:5258–5265. doi: 10.1073/pnas.92.12.5258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Andreev I.A., Ratmanova N.K., Novoselov A.M., Belov D.S., Seregina I.F., Kurkin A.V. Oxidative dearomatization of 4,5,6,7-tetrahydro-1H-indoles obtained by metal- and solvent-free thermal 5-endo-dig cyclization: the route to erythrina and lycorine alkaloids. Chem. – Eur. J. 2016;22:7262–7267. doi: 10.1002/chem.201600273. [DOI] [PubMed] [Google Scholar]
  4. Boyle P., Maisonneuve P., Autier P. Update on cancer control in women. Int. J. Gynecol. Obstet. 2000;70:263–303. doi: 10.1016/s0020-7292(00)00298-8. [DOI] [PubMed] [Google Scholar]
  5. Chakraborty I., Jana S. Synthetic developments on the indolizidine alkaloid, harmicine. Synthesis. 2013;45:3325–3331. [Google Scholar]
  6. Chen Q., Xu L., Liang C., Wang C., Peng R., Liu Z. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat. Commun. 2016;7:1–3. doi: 10.1038/ncomms13193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eicher T., Hauptmann S., Speicher A., editors. The Chemistry of Heterocycles: Structure, Reactions, Synthesis, and Applications. third ed. Wiley-VCH; Weinheim, Germany: 2012. [Google Scholar]
  8. Gomtsyan A. Heterocycles in drugs and drug discovery. Chem. Heterocycl. Compd. 2012;48:7–10. [Google Scholar]
  9. Gralow J., Ozols R.F., Bajorin D.F., Cheson B.D., Sandler H.M., Winer E.P., Bonner J., Demetri G.D., Curran W., Ganz P.A., Kramer B.S. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J. Clin. Oncol. 2008;26:313–325. doi: 10.1200/JCO.2007.15.4088. [DOI] [PubMed] [Google Scholar]
  10. Grossman, S.A., Batara, J.F., 2004. Current management of glioblastoma multiforme. In: Seminars in Oncology, vol. 31, no. 5, pp. 635–644. WB Saunders. [DOI] [PubMed]
  11. Kam T.-S., Sim K.-W. Alkaloids from Kopsia griffithii. Phytochemistry. 1998;47:145–147. [Google Scholar]
  12. Kanavos P. The rising burden of cancer in the developing world. Ann. Oncol. 2006;17(suppl_8):viii15–viii23. doi: 10.1093/annonc/mdl983. [DOI] [PubMed] [Google Scholar]
  13. Kumar R.S., Almansour A.I., Arumugam N. In vitro mechanistic investigation of polycyclic cage-like heterocyclic hybrid possessing diverse pharmacophoric units. J. King Saud Univ. Sci. 2020;32:2406–2413. [Google Scholar]
  14. Lim D.R., Kuk J.K., Kim T., Shin E.J. Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: Which side is better outcome? Medicine. 2017;96:42. doi: 10.1097/MD.0000000000008241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Liu F., Qian X., Cui J., Xiao Y., Zhang R., Li G. Design, synthesis, and antitumor evaluation of novel acenaphtho[1,2-b]pyrrole-carboxylic acid esters with amino chain substitution. Bioorg. Med. Chem. 2006;14:4639–4644. doi: 10.1016/j.bmc.2006.02.016. [DOI] [PubMed] [Google Scholar]
  16. Maier-Hauff K., Rothe R., Scholz R., Gneveckow U., Wust P., Thiesen B., Feussner A., von Deimling A., Waldoefner N., Felix R., Jordan A. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J. Neurooncol. 2007;81:53–60. doi: 10.1007/s11060-006-9195-0. [DOI] [PubMed] [Google Scholar]
  17. Nair J.J., van Staden J., Bastida J. Apoptosis-inducing effects of amaryllidaceae alkaloids. Curr. Med. Chem. 2016;23:161–185. doi: 10.2174/0929867323666151118121124. [DOI] [PubMed] [Google Scholar]
  18. Pereira M.F., Rochais C., Dallemagne P. Recent advances in phenanthroindolizidine and phenanthroquinolizidine derivatives with anticancer activities. AntiCancer Agents Med. Chem. 2015;15:1080–1081. doi: 10.2174/1871520615666150520143600. [DOI] [PubMed] [Google Scholar]
  19. Santiago-Vazquez Y., Das S., Das U., Robles-Escajeda E., Ortega N.M., Lema C., Varela-Ramírez A., Aguilera R.J., Balzarini J., De Clercq E., Dimmock S.G., Gorecki D.K., Dimmock J.R. Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity. Eur. J. Med. Chem. 2014;77:315–322. doi: 10.1016/j.ejmech.2014.03.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sorgi K.L., Maryanoff C.A., McComsey D.F., Graden D.W., Maryanoff B.E. Asymmetric induction in an enammonium-iminium rearrangement. Mechanistic insight via NMR, deuterium labeling, and reaction rate studies. Application to the stereoselective synthesis of pyrroloisoquinoline antidepressants. J. Am. Chem. Soc. 1990;112:3567–3579. [Google Scholar]
  21. Stewart, B.W., Kleihues, P. (Eds.), 2014. World Cancer Report.
  22. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1:389–402. doi: 10.1016/j.stem.2007.08.001. [DOI] [PubMed] [Google Scholar]
  23. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat. 1995;36:169–180. doi: 10.1007/BF00666038. [DOI] [PubMed] [Google Scholar]
  24. Wolinsky J.B., Colson Y.L., Grinstaff M.W. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159:14–26. doi: 10.1016/j.jconrel.2011.11.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Zhang Q., Tu G., Zhao Y., Cheng T. Novel bioactive isoquinoline alkaloids from Carduus crispus. Tetrahedron. 2002;58:6795–6798. [Google Scholar]
  26. Zhang Z., Yang Y., Zhang D., Wang Y., Qian X., Liu F. Acenaphtho[1,2-b]pyrrole derivatives as new family of intercalators: various DNA binding geometry and interesting antitumor capacity. Bioorg. Med. Chem. 2006;14:6962–6970. doi: 10.1016/j.bmc.2006.06.029. [DOI] [PubMed] [Google Scholar]

Articles from Saudi Journal of Biological Sciences are provided here courtesy of Elsevier

RESOURCES